http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-586663-A5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 |
| filingDate | 1973-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1977-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-586663-A5 |
| titleOfInvention | Adamantane derivs. as antiviral agents - from (1)-adamantyl-carboxamidine and an acid chloride |
| abstract | New adamantane derivs. of formula (I) are prepd. by reacting a cpd. of formula (II) with a cpd. of formula (III) Y-C(X)-R1 (III). In the formulae X = O, S; R1 = lower alkyl, aryl (opt. substd. by Cl, Br, I, F, NO2, CF3, lower alkyl), cycloalkyl, -(CH2)n-Hal, -(CH2)n-OR2 or a heterocyclic ring (n = 0, 1-12, Hal = Cl, Br, I, F, R2 = lower alkyl); Y = acid residue of a reactive ester. In an example 1-adamantyl-O-chloracetyl carboxamidine was prepd. from chloracetyl chloride and 1-adamantyl carboxamidine. Cpds. (I) and their acid addn. salts have a low toxicity and can be used to treat viral infections and as a prophylactic for influenze. The daily dose for adults is 100-400 mg pref. administered as 2-3 divided doses of 35-200 mg daily. |
| priorityDate | 1973-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.